Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma

Thursday, June 8, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 8, 2017 /PRNewswire/ -- has issued research reports on Gilead Sciences Inc.

(NASDAQ: GILD), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). According to Oppenheimer's Leah Rush Cann, Biotech stocks are trading at a 30% premium to the market.
The group had a price-to-earnings-growth ratio of 1.86 times versus the S&P 500's PEG ratio 1.43x through the end of May. Access's complimentary reports for today's stocks line-up at:

Gilead Sciences 

Shares in Foster City, California headquartered Gilead Sciences Inc. saw a slight drop of 0.82%, ending Wednesday's trading session at $64.32. The stock recorded a trading volume of 7.78 million shares. The Company's shares are trading 3.06% below their 50-day moving average. Moreover, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle-East, have a Relative Strength Index (RSI) of 39.29.

On June 01st, 2017, Gilead Sciences announced that Kevin Young CBE, COO, and Norbert W. Bischofberger, PhD, Executive Vice President, R&D and Chief Scientific Officer, will participate in a fireside chat at the Goldman Sachs 38th Annual Global Healthcare Conference on June 15th, 2017, at 10:00 a.m. PT in Ranchos Palos Verdes, CA. The audio portion of the fireside chat will be accessible live on the Company's Investors website. Visit us today and access your complete report on GILD for free at:

Aurinia Pharma 

Victoria, Canada headquartered Aurinia Pharmaceuticals Inc.'s stock declined 2.52%, closing the day at $6.20. A total volume of 1.43 million shares was traded. The Company's shares have surged 195.24% since the start of this year. The stock is trading 43.07% above its 200-day moving average. Additionally, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have an RSI of 37.27.

On May 18th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $12 a share to $10 a share.

On June 05th, 2017, Aurinia Pharmaceuticals announced that it presented additional data from its global Phase IIB AURA-LV study in lupus nephritis during the 54th European Renal Association-European Dialysis and Transplant Association Congress in Madrid, Spain. The data were presented on June 04th, 2017 during the late-breaking session by lead author James Tumlin, M.D., a clinical investigator for the study and founder of Southeast Renal Research Institute. The complimentary research report on AUPH can be accessed at:

Esperion Therapeutics 

On Wednesday, shares in Ann Arbor, Michigan headquartered Esperion Therapeutics Inc. (ESPR) recorded a trading volume of 671,240 shares. The stock ended the day 0.92% higher at $36.16. The Company's shares have advanced 4.93% in the past month, 6.29% in the previous three months, and 188.82% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.08% and 74.95%, respectively. Furthermore, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C), have an RSI of 57.52.

On May 22nd, 2017, ESPR provided an update to its shareholders regarding recent trading activity in its common stock. ESPR wishes to assure its shareholders, collaboration partners, and colleagues that the Company remains dedicated to advancing the clinical development of bempedoic acid for patients with hypercholesterolemia who require additional LDL-C lowering and for their treating physicians, and to generating significant long-term value for its shareholders. Register for free on and download the research report on ESPR at:

Alexion Pharma 

New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc.'s stock dropped 1.31%, finishing yesterday's session at $100.14. A total volume of 3.06 million shares was traded, which was above their three months average volume of 2.64 million shares. The Company's shares are trading below their 50-day moving average by 14.15%. Additionally, shares of Alexion Pharma, which develops and commercializes life-transforming therapeutic products, have an RSI of 31.60.

On May 25th, 2017, research firm Morgan Stanley upgraded the Company's stock rating from 'Equal-Weight' to 'Overweight'.

On May 30th, 2017, Alexion Pharma announced that management will present at Goldman Sachs 38th Annual Global Healthcare Conference on June 13th, 2017, at 2:20 p.m. ET in Rancho Palos Verdes. Management will also present at the William Blair 37th Annual Growth Stock Conference on June 14th, 2017, at 12:20 p.m. ET in Chicago. Get free access to your research report on ALXN at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store